New developments in alpha 1-antitrypsin deficiency

Seminars in Respiratory and Critical Care Medicine

Volumn 20, Issue 4, 1999, Pages 301-310

  Aboussouan, Loutfi S ^a   Stoller, James K ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alpha 1 antitrypsin deficiency; Augmentation therapy; Loop sheet polymerization; Lung physiopathology; Lung transplantation; Lung volume reduction

Indexed keywords

ALPHA 1 ANTITRYPSIN; LEUKOCYTE ELASTASE;

AUTOSOMAL INHERITANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; EMPHYSEMA; ENZYME DEFICIENCY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TRANSPLANTATION; LUNG VOLUME; PATHOPHYSIOLOGY; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; UNITED STATES;

EID: 0032776477     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1021327     Document Type: Review

References (71)

1. Laurell CB, Eriksson S. The electrophoretic alpha-1 globulin pattern of serum in alpha 1-anthrypsin deficiency. Scand J Lab Clin Invest 1963;15:132-140
2. 1-antitrypsin deficiency: Pathogenesis and treatment. Hosp Prac 1991;26(2):73-86
3. 1-antitrypsin deficiency. Chest 1996;110(6 suppl):237S-242S
4. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha 1-antitrypsin. Am J Respir Crit Care Med 1998;158:49-59
5. 1-antitrypsin accumulation in the liver. Nature 1992;357:605-607
6. Carrell RW, Whisstock J, Lomas DA. Conformational changes in serpins and the mechanism of alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 1994;150:S171-175
7. 1-antitrypsin deficiency. A conformational disease. Chest 1996;110: 243S-247S
8. 1-antitrypsin deficiency. Hepatology 1996;24:1504-1516
9. 4 by alveolar macrophages. J Clin Invest 1991;88:891-897
10. Goetzl EJ. Modulation of human neutrophil polymorphonuclear migration by human plasma alpha globulin inhibitors and synthetic esterase inhibitors. Immunology 1975;29: 163-174
11. 1-antitrypsin deficiency. Am J Hum Genet 1994;55:126-133
12. Gaillard MC, Kilroe-Smith TA, Nogueira C, Dunn D, Jenkins T, Fine B, Kallenbach J. Alpha-1-protease inhibitor in bronchial asthma: Phenotypes and biochemical characteristics. Am Rev Respir Dis 1992;145:1311-1315
13. Sveger T. Liver disease in alpha 1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976;294:1316-1321
14. Hussain M, Mieli-Vergani G, Mowat AP. Alpha 1-antitrypsin deficiency and liver disease - Clinical presentation, diagnosis and treatment. J Inherit Metab Dis 1991;14:497-511
15. Brandy ML, Paul LD, Miller BH, Falk BH, Wu M, Crystal RG. Clinical features and history of the destructive lung disease associated with alpha 1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988;138: 327-336
16. Gishen P, Saunders AJS, Tobin MJ, Hutchison DCS. Alpha 1-antitrypsin deficiency: The radiological features of pulmonary emphysema in subjects of PI-type Z and PI-type SZ: A survey by the British Thoracic Association. Clin Radiol 1982;33:371-377
17. 1-antitrypsin deficiency. Chest 1995;107:535-545
18. Larsson C. Natural history and life expectancy in severe alpha 1-antitrypsin deficiency, PI*Z. Acta Med Scand 1978;204: 345-356
19. Fallat RL. Reactive airways disease and alpha 1-antitrypsin deficiency. In Crystal RG (ed): Alpha 1-antitrypsin deficiency: Biology, pathogenesis, clinical manifestations, therapy. New York: Marcel Dekker, Inc., 1996;88, pp 259-279
20. Eden E, Mitchell D, Mehlman B, Khouli H, Nejat M, Grieco MH, Turino GM. Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med 1997;156:68-74
21. King MA, Stone JA, Diaz PT, Mueller CF, Becker WJ, Gadek JE. Alpha 1-antitrypsin deficiency: Evaluation of bronchiectasis with CT. Radiology 1996;199:137-141
22. Shin MS, Ho KJ. Bronchiectasis in patients with alpha 1-antitrypsin deficiency. A rare occurrence? Chest 1993;104: 1384-1386
23. 1-antitrypsin deficiency. Mayo Clin Proc 1994;69:1040-1043
24. Schievink WI, Katzmann JA, Piepgras DG, Schaid DJ. Alpha-1-antitrypsin phenotypes among patients with intracranial aneurysms. J Neurosurg 1996;84:781-784
25. Schievink WI, Prakash UB, Piepgras DG, Mokri B. Alpha 1-antitrypsin deficiency in intracranial aneurysma and cervical artery dissection. Lancet 1994;343:452-453
26. 1-antitrypsin phenotypes in patients with abdominal aortic aneurysms. J Surg Res 1990;49:319-321
27. 1-antitrypsin deficiency-associated panniculitis: Case report and review of literature. Pediatr Dermatol 1991;8:296-299
28. 1-antitrypsin deficiency. Clin Genet 1980;17:153-160
29. 1-antitrypsin deficiency. Hum Pathol 1992;23:57-62
30. 1-antitrypsin associated with cutaneous vasculitis, rapidly progressive glomerulonephritis, and colitis. Am J Med 1985;79: 489-494
31. Hwang ST, Williams ML, McCalmont TH, Frieden IJ. Sweet's syndrome leading to acquired cutis laxa (Marshall's syndrome) in a child with alpha 1-antitrypsin deficiency. Arch Dermatol 1995;131:1175-1177
32. Rabassa AA, Schwartz MR, Ertan A. Alpha 1-antitrypsin deficiency and chronic pancreatitis. Dig Dis Sci 1995;40; 1997-2001
33. Esnault VL, Audrain MA, Sesboue R. Alpha 1-antitrypsin phenotyping in ANCA-associated diseases: One of several arguments for protease/antiprotease imbalance in systemic vasculitis. Exp Clin Immunogen 1997;14:206-213
34. Elzouki AN, Segalmark M, Mazodier P, Eriksson S. Wegener's granulomatosis in a patient with severe PiZZ alpha 1-antitrypsin deficiency. QJM 1996;89:877
35. th ed. New York: McGraw-Hil), 1983, pp 1450-1467
36. Brantly M. In Report of a WHO meeting on alpha 1-antitrypsin deficiency. Geneva: Human Genetics Programme Division of Noncommunicable Diseases, World Health Organization, March 18-20, 1996
37. 1-antitrypsin deficiency. Roger S. Mitchell Lecture. Chest 1997;111 (6 Suppl):123S-128S
38. Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: Results of a mail survey of the readership of a national newsletter. Cleve Clin J Med 1994;61:461-467
39. 1-antitrypsin deficiency deaths in the United States from 1979-1991. An analysis using multiple-cause mortality data. Chest 1996;110:78-83
40. Thelin T, Sveger T, McNeil TF. Primary prevention in a high-risk group: Smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency (ATD). Acta Pædiatr 1996;85:1207-1212
41. Hubbard RC, Ogushi F, Fells GA, Cantin AM, Jallat S, Courtney M, Crystal RG. Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase. J Clin Invest 1987;80:1289-1295
42. Edmonds BK, Hodge JA, Rietschel RL. Alpha 1-antitrypsin deficiency-associated panniculitis: Case report and review of the literature. Ped Dermatol 1991;8:296-299
43. Pittelkow MR, Smith KC, Su WP. Alpha 1-antitrypsin deficiency and panniculitis. Perspectives on disease relationship and replacement therapy. Am J Med 1988; 84(6A):80-86
44. Hubbard RC, Crystal RG. Alpha 1-antitrypsin augmentation therapy for alpha 1-antitrypsin deficiency. Am J Med 1988;84(6A):52-62
45. 1-antitrypsin deficiency. Chest 1997;112:607-613
46. Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG. Biochemical efficacy and safety of monthly augmentation therapy for alpha-1 antitrypsin deficiency. JAMA 1988; 260:1259-1264
47. Canadian Thoracic Society. Current status of alpha 1-antitrypsin replacement therapy recommendations for the management of patients with severe hereditary deficiency. Can Med Assoc J 1992;146:841-844
48. American Thoracic Society-Official Statement. Guidelines for the approach to the patients with severe hereditary alpha-1-antitrypsin deficiency. Am Rev Respir Dis 1989;140: 1494-1497
49. 1-antitrypsin deficiency? Eur Respir J 1997;10:2260-2263
50. rd, Franzblau C, Snider GL. Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1-antitrypsin deficient humans. Respiration 1995;62:76-79
51. Schwaiblmair M, Vogelmeier C, Fruhmann G. Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency - three year follow-up. Respiration 1997;64:10-15
52. Vogelmeier C, Kirlath I, Warrington S, Banik N, Ulbrich E, Du Bois RM. The intrapulmonary half-life and safety of aerosolized α1-protease inhibitor in normal volunteers. Am J Respir Crit Care Med 1997;155:536-541
53. Hubbard RC, Brantly ML, Sellers SE, Mitchell ME, Crystal RG. Anti-neutrophil-elastase defenses of the lower respiratory tract in α1-antitrypsin deficiency directly augmented with an aerosol of α1-antitrypsin. Ann Intern Med 1989;111:206-212
54. Hubbard RC, McElvaney NG, Sellers SE, Healy JT, Czerski DB, Crystal RG. Recombinant DNA-produced alpha 1-antitrvpsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency. J Clin Invest 1989;84: 1349-1354
55. Crystal RG. Gene therapy strategies for pulmonary disease. Am J Med 1992;92(suppl 6A):44S-52S
56. Setoguchi Y, Jaffe HA, Chu C-S, Crystal RG. Intraperitoneal in vivo gene therapy to deliver α1-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 1994;10:369-377
57. Canonico AE, Canary JT, Meyrick BO, Brigham KL. Aerosol and intravenous transfection of human (1-antitrypsin gene to lungs of rabbits. Am J Respir Cell Mol Biol 1994;10: 24-29
58. Rosenfeld MA, Siefried W, Yoshimura K, Yoneyama K, Fukuyama M, Stier LE, Pääkkö PK, Gilardi P, Stratford-Perricaudet LD, Perricaudet M, Jallat S, Pavirani A, Lecocq J-P, Crystal RG. Adenovirus-mediated transfer of a recombinarit (1-antitrypsin gene to the lung epithelium in vivo. Science 1991;252:431-434
59. Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin P-types in 965 COPD patients. Chest 1986;89:370-373
60. Hosenpud JD, Bennett LE, Keck BM, Biol B, Novick RJ. The Registiy of the International Society for Heart and Lung Transplantation: Fourteenth official report-1997. J Heart Lung Transplan 11997;16:691-712
61. 1-antitrypsin deficiency emphysema. Chest 1996;110;284S-294S
62. King MB, Campbell EJ, Gray BH, Hertz MI. The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients. Am J Respir Crit Care Med 1994;149:966-971
63. Cooper JD, Patterson GA, Sundaresan RS, Trulock EP, Yusen RD, Pohl MS, Lefrak SS. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. J Thorac Cardiovasc Surg 1996;112: 1319-1330
64. Ferguson GT, Fernandez E, Zamora MR, Pomerantz M, Buchholz J, Make BJ. Improved exercise performance following lung volume reduction surgery for emphysema. Am J Respir Crit Care Med 1998;157:1195-1203
65. Laghi F, Jubran A, Topeli A, Fahey PJ, Garrity ER Jr, Arcidi JM, de Pinto DJ, Edwards LC, Tobin MJ. Effects of lung volume reduction surgery on neuromechanical coupling of the diaphragm. Am J Respir Crit Care Med 1998;157: 475-483
66. Criner G, Cordova FC, Leyenson V, Roy B, Travaline J, Sudarshan S, O'Brien G, Kuzam AM, Furukawa S. Effect of lung volume reduction surgery on diaphragm strength. Am J Respir Crit Care Med 1998;157:1578-1585
67. Sciurba FC, Rogers RM, Keenan RJ, Slivka WA: Gorcsan III J, Ferson PF, Holbert JM, Brown ML, Landreneau RJ. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N Engl J Med 1996;334:1095-1099
68. Fessier HE, Permutt S. Lung volume resection surgery and airflow limitation. Am J Respir Crit Care Med 1998;157: 715-722
69. Bavaria JE, Pochettino A, Kotloff RM, Rosengard BR, Wahl PM, Roberts JR, Palevsky HI, Kaiser LR. Effect of volume reduction on lung transplant timing and selection for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1998;115:9-18
70. 1-antitrypsin deficiency as assessed by annual CT. Acta Radiologica 1997;38: 826-832
71. Wulfsberg EA, Hoffmann DE, Cohen MM. Alpha 1-antitrypsin deficiency. Impact of genetic discovery on medicine and society. JAMA 1994;271:217-222